{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T13:26:47Z","timestamp":1780493207977,"version":"3.54.1"},"reference-count":23,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"2","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Background: Recent studies have shown that increased circulating concentrations of fibroblast growth factor 21 (FGF21) are associated with obesity, metabolic disorder, and atherosclerosis. However the relationship between FGF21 and coronary artery disease (CAD) is controversial This study was planned to investigate the role of FGF21 in CAD development and CAD severity. Methods: Seventy-eight patients with stable angina pectoris (SAP) (lesion positive) and 40 control patients (lesion negative) with similar cardiovascular risk factors were included in the study. Serum FGF21 levels were measured by ELISA method. CAD severity was evaluated by using SYNTAX and GENSINI risk scores. Results: FGF21 concentrations were found significantly higher in the SAP group than in the control group. [101.18 \u00b1 141.62 vs. 47.93 \u00b1 58.74 pg\/mL; p = 0.03], no correlation was found between the SYNTAX (r = 0.146 and p = 0.134) and GENSINI (r = 0.211 and p = 0.084) scores with serum FGF21 levels. There was a negative relationship between serum FGF21 and serum HDL-C levels in correlation analysis (r = - 0.272; p = 0.026). Conclusions: The serum FGF21 levels are different between SAP and control patients. FGF21 is a marker for CAD diagnosis, but not for the evaluation of CAD severity.<\/jats:p>","DOI":"10.5937\/jomb0-30191","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T08:50:33Z","timestamp":1631868633000},"page":"162-167","source":"Crossref","is-referenced-by-count":8,"title":["Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease?"],"prefix":"10.5937","volume":"41","author":[{"given":"Gokay","family":"Nar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Sara","given":"Sanlialp","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukiye","family":"Nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguz","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Mehmet","given":"Ozen","family":"Furkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guven","family":"Gunver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Cihan","given":"Sevgican","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442.;","DOI":"10.1371\/journal.pmed.0030442"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Domouzoglou EM, Naka KK, Vlahos AP, et al. Fibroblast growth factors in cardiovascular disease: The emerging role of FGF21. Am J Physiol Heart Circ Physiol 2015; 309: 1029-38.;","DOI":"10.1152\/ajpheart.00527.2015"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Jing C, X Su, Lei Q, et al. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Bioscience Reports (2018) 38 BSR20181099;","DOI":"10.1042\/BSR20181099"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic andregulatory pathways. Physiol Rev 2006; 86: 51-81.;","DOI":"10.1152\/physrev.00024.2005"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Weber C, Zernecke A, Libby P. The multifaceted contributionsof leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-15.;","DOI":"10.1038\/nri2415"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Crickx E, Saussine A, Vignon-Pennamen MD, et al. Diffuse dermal angiomatosis associated with severe atherosclerosis: Two cases and review of the literature. Clin Exp Dermatol 2015; 40: 521-24.;","DOI":"10.1111\/ced.12565"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Itoh N, Ornitz DM. Evolution of the FGF and FGFr gene families. Trends Genet 2004; 20: 563-9.;","DOI":"10.1016\/j.tig.2004.08.007"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Shen Y, Ma X, Zhou J, et al. Additive relationship between serum fibroblast growth factor 21 level and coro nary artery disease. Cardiovasc Diabetol 2013; 12: 124. doi: 10.1186\/1475-2840-12-124.;","DOI":"10.1186\/1475-2840-12-124"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Li H, Zhang J, Jia W. Fibroblast growth factor 21: A novel metabolic regulator from pharmacology to physiology. Front Med. 2013; 7: 25-30.;","DOI":"10.1007\/s11684-013-0244-8"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Bobbert T, Schwarz F, Fischer-Rosinsky A, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and type 2 diabetes in Caucasians. Diabetes Care 2013; 36(1): 145-9.;","DOI":"10.2337\/dc12-0703"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Khalaf MM, Fayez S, Azou T. Serum Fibroblast Growth Factor 21 as a Novel Biomarker in Prediction of Coronary Artery Disease Severity. British Journal of Medicine & Medical Research 2016; 18(9): 1-11.;","DOI":"10.9734\/BJMMR\/2016\/29581"},{"key":"ref12","unstructured":"SYNTAX working group. SYNTAX score calculator. Accessed May 20, 2012.;"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Gensini GG. Coronary arteriography: role in myocardial revascularization. Postgrad Med 1978; 63(1):121-8.;","DOI":"10.1080\/00325481.1978.11714729"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Qing L, Yuan Z, Ding D, et al. Association Between Serum Fibroblast Growth Factor 21 and Mortality Among Patients With Coronary Artery Disease. J Clin Endocrinol Metab 2016; 101(12): 4886-94.;","DOI":"10.1210\/jc.2016-2308"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Vasanthi M, Adole PS, Pandit VR, Vinod KV. Assessment of serum tenascin-C and growth differentiation factor-15 among type 2 diabetes mellitus patients with and without acute coronary syndrome. J Med Biochem 2020; 39(4): 460-6.;","DOI":"10.5937\/jomb0-24662"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"An SY, Lee MS, Yi SA, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96: 196-203.;","DOI":"10.1016\/j.diabres.2012.01.004"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lee Y, Lim S, Hong ES, et al. Serum FGF21 concentration is associated with hypertriglyceridaemia, hyperinsulinaemia and pericardial fat accumulation, independently of obesity, but not with current coronary artery status. Clinical Endocrinology 2014; 80: 57-64.;","DOI":"10.1111\/cen.12134"},{"key":"ref18","unstructured":"Matej Stanc\u00edk. Fibroblast growth factor 21 in prediction of coronary angiography result in stable coronary artery disease patients. Biomed Res DOI: 10.4066\/biomedicalresearch-C7-020.;"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Jing Cheng, Xing Su, Lei Qiao, Chungang Zhai, Wenqiang Chen. Circulating level of fibroblast growth factor 21 is independently associated with the risks of unstable angina pectoris. Biosci Rep 2018 Oct 31; 38(5).;","DOI":"10.1042\/BSR20181099"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Miyazaki Y, Saita E, Kishimoto Y, et al. Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. Journal of atherosclerosis and thrombosis. 2018; (25): 9: 821-8.;","DOI":"10.5551\/jat.41731"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Park SD, Bae KH, Choi YK et al. Relationship between Circulating FGF21 Concentrations and the Severity of Coronary Artery Damage in Subjects with Cardio vascular Disease. J Lipid Atheroscler 2018; 7(1): 42-9.;","DOI":"10.12997\/jla.2018.7.1.42"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kim WJ, Kim SS, Lee HC, et al. Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes. J Korean Med Sci 2015; 30: 586-90.;","DOI":"10.3346\/jkms.2015.30.5.586"},{"key":"ref23","unstructured":"Matuszek B, Lenart-Lipi\u0144ska M, Duma D, et al. Evaluation of concentrations of FGF21 a new adipocytokine in type 2 diabetes. Polish Journal of Endocrinology 2010; 61: 50-4.;"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Da li je rast fibroblastnog serumskog faktora 21 povezan sa te\u017einom ili prisustvom koronarnog arterijskog oboljenja"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/30191\/18611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2022\/1452-82582202162N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T19:53:35Z","timestamp":1649447615000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582202162N"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-30191","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}